<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Coya Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Coya Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/coya-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835587e78dffbe2df0eaa1f.webp</url>
<title>Coya Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-publication-demonstrating-correlation-between-longitudinal-biomarker-data-and-clinical-outcomes-supporting-the-mechanistic-rationale-for-coya-302-in-patients-with-als</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-publication-demonstrating-correlation-between-longitudinal-biomarker-data-and-clinical-outcomes-supporting-the-mechanistic-rationale-for-coya-302-in-patients-with-als</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and</description>
</item>
<item>
<title>Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-planned-board-transition-and-appointment-of-mark-h-pavao-as-independent-director-63</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-planned-board-transition-and-appointment-of-mark-h-pavao-as-independent-director-63</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Howard Berman, Ph.D., the Company’s Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition</description>
</item>
<item>
<title>Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-publication-demonstrating-regulatory-t-cell-dysfunction-and-systemic-inflammation-in-frontotemporal-dementia-supporting-mechanistic-rationale-for-coya-302-immune-restoring-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-publication-demonstrating-regulatory-t-cell-dysfunction-and-systemic-inflammation-in-frontotemporal-dementia-supporting-mechanistic-rationale-for-coya-302-immune-restoring-therapy</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and</description>
</item>
<item>
<title>Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-provides-a-corporate-update-and-reports-fiscal-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-provides-a-corporate-update-and-reports-fiscal-2025-financial-results</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics</description>
</item>
<item>
<title>Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-host-webinar-leading-130000641</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-host-webinar-leading-130000641</guid>
<pubDate>Tue, 10 Feb 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, February 10, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorder, today announced it will host a live webinar on February 17, 2026 at 3:00 p.m. ET/ 12:00 p.m. PT exploring the evolving ALS treatment landscape.</description>
</item>
<item>
<title>Coya Therapeutics Announces $11.1 Million Private Placement</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-11-1-130000952</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-11-1-130000952</guid>
<pubDate>Fri, 30 Jan 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, January 30, 2026--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today that it has entered into a definitive securities purchase agreement for the purchase and sale of an aggregate of 2,522,727 shares of its common stock in a private placement at a price of $4.40 per share. The offering is expecte</description>
</item>
<item>
<title>Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-ceo-dr-arun-130000448</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-ceo-dr-arun-130000448</guid>
<pubDate>Tue, 20 Jan 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, January 20, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter to stockholders from Chief Executive Officer Dr. Arun Swaminathan.</description>
</item>
<item>
<title>Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-results-investigator-130000486</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-results-investigator-130000486</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, January 08, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced positive results of an investigator-initiated proof of concept open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in 9 patients with Frontotemporal Dementia (FTD) over a 6 month period. The study was led by</description>
</item>
<item>
<title>Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-u-fda-130000336</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-u-fda-130000336</guid>
<pubDate>Mon, 05 Jan 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, January 05, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that the U.S. Food and Drug Administration (FDA) has accepted the Company’s IND for COYA 302 for the treatment of frontotemporal dementia (FTD).</description>
</item>
<item>
<title>Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-receives-clinical-trial-130000335</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-receives-clinical-trial-130000335</guid>
<pubDate>Tue, 23 Dec 2025 13:00:00 GMT</pubDate>
<description>HOUSTON, December 23, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces that Health Canada has accepted, without objection, the Clinical Trial Application (CTA) for COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The CTA acceptance by Health Canada allows for activation of clinical si</description>
</item>
<item>
<title>Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-patients-dosed-130000167</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-patients-dosed-130000167</guid>
<pubDate>Tue, 09 Dec 2025 13:00:00 GMT</pubDate>
<description>HOUSTON, December 09, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced that dosing of ALS patients in the Company’s ALSTARS Trial of COYA 302 has commenced.</description>
</item>
<item>
<title>Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-participate-upcoming-investor-130000793</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-participate-upcoming-investor-130000793</guid>
<pubDate>Tue, 25 Nov 2025 13:00:00 GMT</pubDate>
<description>HOUSTON, November 25, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company’s management team will participate in two upcoming conferences.</description>
</item>
<item>
<title>Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-reports-third-quarter-130000438</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-reports-third-quarter-130000438</guid>
<pubDate>Wed, 12 Nov 2025 13:00:00 GMT</pubDate>
<description>HOUSTON, November 12, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) (Coya or the Company), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, provides a corporate update and announces its financial results for the quarter ended September 30, 2025.</description>
</item>
<item>
<title>Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-combination-ld-130000932</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-combination-ld-130000932</guid>
<pubDate>Tue, 04 Nov 2025 13:00:00 GMT</pubDate>
<description>HOUSTON, November 04, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of an in vivo animal study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA investigational proprietary biologic combination) in a well-characterized in vivo lipopolysaccharide (LPS) preclinical mouse model of systemic and neurologic inflammation. Re</description>
</item>
<item>
<title>Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-closing-23-200100424</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-closing-23-200100424</guid>
<pubDate>Mon, 27 Oct 2025 20:01:00 GMT</pubDate>
<description>HOUSTON, October 27, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced the closing of its $23.0 million underwritten public offering of 4,181,818 shares of its common stock, including 545,454 additional shares of its common stock issued pursuant to the full exercise by the underwriter of its optio</description>
</item>
<item>
<title>Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-pricing-20-103000954</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-pricing-20-103000954</guid>
<pubDate>Fri, 24 Oct 2025 10:30:00 GMT</pubDate>
<description>HOUSTON, October 24, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that it has priced an underwritten public offering of 3,636,364 shares of its common stock at a public offering price of $5.50 per share of common stock. Coya has granted the underwriter a 30-day option to purchase up to 545,45</description>
</item>
<item>
<title>Coya Therapeutics Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-proposed-public-203100522</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-proposed-public-203100522</guid>
<pubDate>Thu, 23 Oct 2025 20:31:00 GMT</pubDate>
<description>HOUSTON, October 23, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common</description>
</item>
<item>
<title>Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-congratulates-scientific-advisor-120000208</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-congratulates-scientific-advisor-120000208</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, October 07, 2025--Coya Therapeutics, Inc. (NASDAQ: COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs) which protect the body from autoimmune diseases. This discovery has reshaped modern immunology and opened new therapeutic frontiers.</description>
</item>
<item>
<title>Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-completion-patient-120000246</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-announces-completion-patient-120000246</guid>
<pubDate>Mon, 29 Sep 2025 12:00:00 GMT</pubDate>
<description>Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces completion of patient enrollment of an investigator-initiated, proof-of-concept, open-label study with low-dose IL-2 and CTLA4-Ig combination treatment in patients with Frontotemporal Dementia (FTD). The study is led by Dr. Alireza Faridar and Dr. Stanley Appe</description>
</item>
<item>
<title>Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis</title>
<link>https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-launches-alstars-trial-120000732</link>
<guid isPermaLink="true">https://6ix.com/company/coya-therapeutics-inc-common-stock/news/coya-therapeutics-launches-alstars-trial-120000732</guid>
<pubDate>Mon, 22 Sep 2025 12:00:00 GMT</pubDate>
<description>Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announced today the launch of the ALSTARS Trial, a Phase 2, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov Identifier: NCT 07161999).</description>
</item>
</channel>
</rss>